Exploration of adverse event profiles for glofitamab: A disproportionality analysis using the FDA adverse event reporting system [PDF]
PLoS ONEBackgroundGlofitamab offers a promising option for the treatment of diffuse large B-cell lymphoma. It is crucial to gather comprehensive safety information of glofitamab through large-scale post market monitoring.MethodsThis study conducted a ...
Meng Zhou, Cheng Jiang, Chuanyong Su
doaj +3 more sources
Adverse event reporting of mirtazapine: A disproportionality analysis of FDA adverse event reporting system (FAERS) database from 2004-2024. [PDF]
PLoS ONEBackgroundMirtazapine is a pharmacological agent commonly utilized as a first-line treatment for major depressive disorder, exhibiting both noradrenergic and selective serotonergic activity.
Keying Guo +5 more
doaj +2 more sources
Adverse Event Signals Associated with Beta-Lactamase Inhibitors: Disproportionality Analysis of USFDA Adverse Event Reporting System [PDF]
Journal of XenobioticsBackground: Beta-lactamase inhibitors (BLIs) are widely used with beta-lactam antibiotics to combat resistant infections, yet their safety profiles, especially for newer agents, remain underexplored.
Kannan Sridharan, Gowri Sivaramakrishnan
doaj +2 more sources
Adverse event prediction in propofol-remimazolam tosilate anesthesia [PDF]
Frontiers in MedicineObjectiveThis study aimed to develop and validate a predictive model for anesthesia-related adverse events (ARAEs) in patients receiving propofol combined with remimazolam tosilate, based on perioperative clinical indicators.MethodsA retrospective study ...
Minmin Zhai +2 more
doaj +2 more sources
Safety assessment of gemtuzumab ozogamicin: real-world adverse event analysis based on the FDA Adverse Event Reporting System [PDF]
Frontiers in MedicineObjectiveTo mine adverse drug events (ADEs) following the use of gemtuzumab ozogamicin based on the FDA Adverse Event Reporting System (FAERS), and to provide references for the safety assessment of clinical drug use.MethodsWe obtained reports of adverse
Xuexue Liu +10 more
doaj +2 more sources
Safety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea [PDF]
Clinical and Experimental Pediatrics, 2023 As of June 2022, 5 coronavirus disease 2019 (COVID-19) vaccine brands have been used in Korea’s national immunization program. The Korea Disease Control and Prevention Agency has enhanced vaccine safety monitoring through a passive web-based reporting ...
Yeon-Kyeng Lee +10 more
doaj +1 more source
COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021 [PDF]
Osong Public Health and Research Perspectives, 2021 Objectives On February 26, 2021, coronavirus disease 2019 (COVID-19) vaccination was started for high-priority groups based on the recommendation of the Advisory Committee on Immunization Practices with 2 available COVID-19 vaccines (AstraZeneca and ...
Hyun-kyung Oh +6 more
doaj +1 more source
Self-reported adverse events after 2 doses of COVID-19 vaccine in Korea [PDF]
Epidemiology and Health, 2022 OBJECTIVES In Korea, a national coronavirus disease 2019 (COVID-19) vaccination program was implemented, including 4 vaccines against COVID-19. A text messaging-based survey, in addition to a passive adverse event reporting system, was launched to ...
Yunhyung Kwon +7 more
doaj +1 more source
Safety monitoring of COVID-19 vaccination among adolescents aged 12 to 17 years old in the Republic of Korea [PDF]
Osong Public Health and Research Perspectives, 2022 Objectives This study aimed to disseminate information on coronavirus disease 2019 (COVID-19) vaccine safety among adolescents aged 12 to 17 years in the Republic of Korea.
Seontae Kim +4 more
doaj +1 more source
Adverse events of the Pfizer-BioNTech COVID-19 vaccine in Korean children and adolescents aged 5 to 17 years [PDF]
Osong Public Health and Research Perspectives, 2022 Objectives This study aimed to identify potential safety signals and adverse events following the primary Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccination series among children and adolescents aged 5 to 17 years in the Republic of Korea ...
Seontae Kim +5 more
doaj +1 more source